Applied Therapeutics Stock (NASDAQ:APLT)


RevenueOwnershipFinancialsChart

Previous Close

$9.63

52W Range

$1.79 - $9.98

50D Avg

$7.62

200D Avg

$5.68

Market Cap

$1.11B

Avg Vol (3M)

$2.57M

Beta

2.04

Div Yield

-

APLT Company Profile


Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

31

IPO Date

May 14, 2019

Website

APLT Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23
License$9.22M
Research and Development Services$774.00K

Fiscal year ends in Dec 23 | Currency in USD

APLT Financial Summary


Dec 23Dec 22Dec 21
Revenue$9.99M--
Operating Income$-64.53M$-82.95M$-105.62M
Net Income$-119.76M$-81.69M$-104.61M
EBITDA$-64.53M$-82.88M$-105.62M
Basic EPS-$-2.16$-4.09
Diluted EPS-$-2.16$-4.09

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
PMVPPMV Pharmaceuticals, Inc.
XFORX4 Pharmaceuticals, Inc.
CGEMCullinan Oncology, Inc.
SEERSeer, Inc.
BCABBioAtla, Inc.
MLYSMineralys Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
HOOKHOOKIPA Pharma Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
GANXGain Therapeutics, Inc.
TERNTerns Pharmaceuticals, Inc.
ORICORIC Pharmaceuticals, Inc.
LTRNLantern Pharma Inc.
CCCCC4 Therapeutics, Inc.
TFFPTFF Pharmaceuticals, Inc.
INABIN8bio, Inc.
VINCVincerx Pharma, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
MOLNMolecular Partners AG
LIFEaTyr Pharma, Inc.
LYRALyra Therapeutics, Inc.
STTKShattuck Labs, Inc.